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ABSTRACT 
Background:  Peritoneal fibrosis is a serious complication of long-term peritoneal 
dialysis, yet the precise pathogenic mechanisms of peritoneal fibrosis remain unknown.  
Fibrocytes participate in tissue fibrosis and express chemokine receptors that are 
necessary for their migration.  The p38 mitogen-activated protein kinase (MAPK) 
pathway regulates the production of chemokines, and it has been demonstrated to 
contribute to the pathogenesis of different fibrotic conditions.  Accordingly, we 
examined the dependency of p38MAPK signaling in fibrocytes using an experimental 
mouse model of peritoneal fibrosis.   
Methods:  Peritoneal fibrosis was induced in mice by the injection of 0.1% 
chlorhexidine gluconate (CG) into the abdominal cavity.  Mice were treated with 
FR167653, a specific inhibitor of p38MAPK, and immunohistochemical studies were 
performed to detect fibrocytes as well as phosphorylated p38MAPK-positive cells.  
The involvement of p38MAPK in the activation of fibrocytes also was investigated in 
vitro. 
Results:  Fibrocytes infiltrated in the peritoneum in response to CG, and this response 
was accompanied by progressive peritoneal fibrosis.  The phosphorylation of 
p38MAPK was detected both in peritoneal mesothelial cells and in fibrocytes, as 
defined by CD45-positive spindle-shaped cells.  The level of peritoneal expression of 
CCL2, which is a chemoattractant for fibrocytes, was up-regulated by CG injection, and 
treatment with FR167653 reduced the number of phosphorylated p38MAPK-positive 
cells, peritoneal CCL2 expression, and the extent of peritoneal fibrosis.  Pre-treatment 
with FR167653 inhibited transforming growth factor-1-induced expression of 
pro-collagen type I 1. 
Conclusions:  These results suggest that p38MAPK signaling contributes to peritoneal 








Peritoneal dialysis (PD) is a beneficial treatment for patients with end-stage renal 
diseases.  Long-term PD treatment causes histopathological alterations in the 
peritoneum, including fibrosis, which is associated with ultrafiltration failure and loss of 
the dialytic capacity in the peritoneum [1,2].  Encapsulating peritoneal sclerosis (EPS) 
also can develop, this causes an ileus and is associated with high mortality [3].  The 
precise pathogenic mechanisms that underlie the development of progressive peritoneal 
fibrosis remain unknown. 
Circulating fibrocytes have been reported to be involved in various fibrotic diseases 
such as idiopathic pulmonary fibrosis, renal fibrosis, and hypertrophic scarring [4-7].  
Fibrocytes comprise a minor fraction of the circulating pool of leukocytes and share 
markers of myeloid (e.g., CD45 and CD34) and mesenchymal (e.g., type I collagen (Col 
I) and fibronectin) cells [4-8].  Additionally, fibrocytes express chemokine receptors 
(e.g., CCR2, CCR5, CXCR4, and CCR7) that are involved in the recruitment of 
fibrocytes to sites of fibrosis [4-7,9].  To date, the potential involvement of fibrocytes 
in peritoneal fibrosis has not been investigated. 
The p38 mitogen-activated protein kinase (MAPK) mediates an important 
intracellular signal transduction pathway by which signals from environmental stimuli 
are transmitted to the nucleus.  At least three distinct groups of MAPKs have been 
identified; extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), 
and p38MAPK [10].  The activation of p38MAPK is involved in apoptosis, stress 
responses, and inflammation [10].  Recent studies have revealed that p38MAPK 
phosphorylation is essential for the production of various chemokines including 
monocyte chemoattractant protein (MCP)-1/CCL2, and for the signal transduction of 
chemokine receptor such as CCR2, which is a cognate receptor for CCL2 [11-16].  In 
addition, p38MAPK has been demonstrated to contribute to the pathogenesis of fibrotic 
conditions [17-21].  Taken together, these findings prompted us to examine the 
involvement of p38MAPK signaling in fibrocyte function and the pathogenesis of 
peritoneal fibrosis.  We evaluated peritoneal fibrosis induced in mice by intraperitoneal 
injection of chlorhexidine gluconate (CG), which is a well-known model of peritoneal 
fibrosis [22].  We report herein that p38 MAPK signaling mediates fibrocyte function 
in the pathogenesis of peritoneal fibrosis and that blockade of p38MAPK signaling may 
be a beneficial approach for the treatment of progressive, peritoneal fibrosis. 
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SUBJECTS AND METHODS 
Peritoneal fibrosis in murine model 
Inbred male C57BL/6 mice (8 weeks, 20-25g) were obtained from Charles River 
Japan (Atsugi, Kanagawa, Japan).  Peritoneal fibrosis was induced by intraperitoneal 
injection of 0.1% CG dissolved in 15% ethanol/saline every other day, over a period of 
21 days as described previously [22,23].  A specific p38MAPK inhibitor, FR167653 
(16 and 32 mg/kg per day), dissolved in drinking water, was orally administrated from 2 
days before CG injection [15,16,24].  Mice in each group (Day 0; n=5, CG mice; n=9, 
CG+FR mice; n=10) were sacrificed 21 days after CG injection.  All procedures used 
in the animal experiments complied with the standards set out in the Guidelines for the 
Care and Use of Laboratory Animals of Kanazawa University. 
 
Tissue preparation 
One portion of the peritoneal tissue was fixed in 10% buffered formalin (pH 7.2), 
embedded in paraffin, cut at 4 m, stained with hematoxylin and eosin or Mallory-Azan 
and observed under a light microscope.  The thickness of the submesothelial 
collagenous zone above the abdominal muscle layer in cross-sections of the abdominal 
wall was defined as peritoneal thickness, as described previously [22].  In each image, 
peritoneal thickness was measured at 10 different points.  Peritoneal cross-sections 
were observed by two investigators and averaged to determine the peritoneal thickness.  
Measurement of the peritoneal thickness was performed by image analysis using Mac 
Scope version 6.02 (Mitani shoji Co., Fukui, Japan). 
 
Detection of fibrocytes in the peritoneum by immunohistochemical studies 
Fibrocytes were identified in tissue samples by dual immunohistochemical 
techniques using specific antibodies against CD45 and Col I as previously described [5].  
For this analysis, formalin-fixed, paraffin-embedded sections were prepared as 
described previously.  Briefly, tissue sections were incubated with rat anti-mouse 
CD45 polyclonal antibodies (R&D Systems Inc., Minneapolis, USA) and rabbit 
anti-mouse Col I polyclonal antibodies (CHEMICON International, Inc., Temecula, 
California, USA).  CD45 was visualized by incubating sections with fluorescein 
isothianate (FITC)-conjugated donkey anti-rat IgG antibodies (Jackson Immunoreseach 
Laboratory, Inc. West Grove, Pennsylvania, USA).  Col I was visualized with 
Cy3-conjugated donkey anti-rabbit IgG antibodies (Jackson Immunoreseach 
Laboratory).  The number of fibrocytes in the peritoneum was counted in all fields of 
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the submesothelial zone, and expressed as the mean number ± standard error 
(SEM)/mm
2
.  In addition, dual-immunostainings for CCR2 and Col I was performed to 
characterize fibrocytes in the peritoneum.  The tissue sections were incubated with 
goat anti-mouse CCR2 antibody (GeneTex, Inc., Irvine, California, USA) and rabbit 
anti-mouse Col I polyclonal antibodies (CHEMICON International, Inc).  The number 
of CCR2-/Col I-dual positive fibrocytes in the peritoneum was counted in all fields of 





Detection of phosphorylated p38MAPK-positive cells 
Immunohistochemistry for phosphorylated p38MAPK (p-p38MAPK) was 
performed to clarify the localization of p-p38MAPK-positive cells.  Formalin-fixed 
and paraffin-embedded sections were incubated with rabbit anti-mouse p-p38MAPK 
polyclonal antibodies (Cell Signaling Technology Inc. Danvers, Massachusetts, USA).  
The number of p-p38MAPK-positive mesothelial cells was counted and expressed as 
the percentages of total mesothelial cells.  In addition, dual-immunostaining for CD45 
and p-p38MAPK was performed to characterize the p-p38MAPK positive cells.  Of 
these dual-positive cells, CD45- and p-p38MAPK-dual positive spindle-shaped cells 
were regarded as p-p38MAPK-positive fibrocytes.  The number of these cells was 
counted in all fields of the submesothelial zone, and expressed as the mean number ± 
standard error (SEM)/mm
2
.   
 
Detection of CCL2-positive cells 
Immunohistochemistry for CCL2 was performed to clarify the localization of 
CCL2-positive cells.  Formalin-fixed and paraffin-embedded sections were incubated 
with rat anti-mouse CCL2 polyclonal antibodies (Hycult Biotechnology B.V. Uden, The 
Netherlands).   
 
Isolation of human fibrocytes from peripheral blood 
Fibrocytes were harvested and cultured as previously reported [7]. Briefly, total 
peripheral blood mononuclear cells (PBMCs) were isolated from venous blood drawn 
from healthy donors (n=3) by centrifugation on a Ficoll-Metrizonate density gradient 
(d=1.077 g/mL; Lymphoprep; Nycomed, Oslo, Norway) following the manufacture’s 
protocol.  After 2 days of culture on tissue culture flasks in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Gibco BRL Life Tech., Carlsbad, California, USA) 
supplemented 20% heat-inactivated fetal calf serum (FCS) (Gibco BRL Life Tech.), 100 
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U/mL penicillin (Gibco BRL Life Tech.), and 100 g/mL streptomycin (Gibco BRL 
Life Tech.), nonadherent cells were removed by gentle aspiration and media were 
replaced.  After 10-12 days, adherent cells were lifted by incubation in ice-cold 0.05% 
EDTA in PBS.  The crude fibrocyte preparations then were depleted by 
immunomagnetic selection of contaminating T cells, B cells, and monocytes using 
pan-T, anti-CD2; pan-B, anti-CD19; and anti-CD14 monoclonal antibody coated with 
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany).  Cell purity was verified 
by flow cytometry using both mouse anti-human CD45 monoclonal antibody (Becton 
Dickinson, PharMingen) and rabbit anti-human Col I polyclonal antibodies 
(CHEMICON international, Inc.). 
 
Culture condition of fibrocytes 
Purified fibrocytes were incubated with transforming growth factor (TGF)-1 (R&D 
Systems Inc.) in a time dependent manner.  Briefly, purified human fibrocytes 
(1x10
6
/mL) were cultured in 12-well plates (Corning Inc., Corning, New York) in 
DMEM supplemented with 0.5% heat-inactivated FCS (Gibco, BRL) at 37C in a 
humidified atmosphere with 5% CO2 for 0-24 h, and in the presence of TGF-1 (10 
ng/mL).  In parallel experiments, fibrocytes were pretreated with FR167653 (32mg/L) 
and then exposed to TGF-1. 
 
Real-time RT-PCR 
To determine transcripts for the 1 chain of pro-collagen type I (COLIAI) and 
CCL2 in the peritoneum, total RNA was extracted from the whole peritoneum.  
Similarly, total RNA was extracted from cultured human fibrocytes and was analyzed 
for the detection of transcripts of COLIAI.  Quantitative real-time PCR was performed 
on the ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster 
City, California, USA) as previously described [5].  Murine beta-glucuronidase and 
human glyceraldehydes-3-phosphate dehydrogenase were used for PCR controls. 
 
Statistical analysis 
The mean and SEM were calculated on all the parameters determined in this study.   
Statistical analyses were performed using Wilcoxon rank-sum test, Kruskal-Wallis test 






Effect of p38MAPK on peritoneal fibrosis 
Morphologic changes were assessed by hematoxylin and eosin staining or 
Mallory-Azan staining.  In the normal mouse, the peritoneal tissue consisted of a 
peritoneal mesothelial monolayer and an exiguity of connective tissues under the 
mesothelial layer (Figure 1a).  At day 21, the peritoneal samples of wild-type mice 
injected with CG showed marked thickening of the submesothelial compact zone and 
the presence of numerous cells (Figure 1b).  In contrast, the thickness of the 
submesothelial zone as well as the number of infiltrating cells in mice treated with 
FR167653 (CG+FR mice) was significantly less than those of wild-type mice (CG 
mice) (Figure 1c).  The mean peritoneal thickness determined by computer analysis 
was reduced in CG+FR mice as compared with CG mice (Figure 1d).  The effect of 
FR167653 at a dose of 32 mg/kg per day was more marked than that observed in mice 
treated with FR of 16 mg/kg per day.  Therefore, we adopted the data at dose of 32 
mg/kg per day in the following examinations.  The expression of COL1A1 mRNA in 
the peritoneum also was reduced by the treatment with FR167653 (Figure 1e). 
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Figure 1.  Peritoneal thickness and pro-collagen type I 1 (COLIAI) expression in the murine 
peritoneum.   
a: Normal control at day 0 did not show evidence of peritoneal thickness.  b: Peritoneal 
thickness at 21 days after CG injection (CG mice).  c: Peritoneal thickness at 21day treated 
with FR167653 (CG+FR mice).  d: CG injection caused peritoneal thickness in CG mice.  In 
contrast, peritoneal thickness was reduced in CG+FR mice as compared with CG mice .  e: 
The up-regulation of COLIAI mRNA was induced by CG injection and treatment with 
FR167653 reduced the level of COLIAI expression.  Values are mean ±SEM.  * P<0.01.  
**P<0.05.  Original magnifications, X200. 
 
CD45/Col I-dual positive fibrocytes infiltrate the peritoneum 
To examine the presence of fibrocytes in the peritoneum, dual-immunostaining for 
CD45 and Col I was performed.  As originally reported, one of the unique 
characteristics of fibrocytes is their simultaneous expression of both CD45 and Col I 
[4-9].  Accordingly, these cells can be identified in tissue samples by double 
immunohistochemistry using specific antibodies against CD45 and Col I.  CD45/Col 
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I-dual positive fibrocytes infiltrated the peritoneum after CG injection (Figure 2a-c).  
The number of infiltrated fibrocytes increased in accordance with the progression of 
fibrosis after CG injection, and was reduced in CG+FR mice (231.6±27.9/mm2) as 
compared with that in CG mice (616.0±123.0/mm2) (Figure 2d). 
 
CCR2-expressing fibrocytes and peritoneal CCL2 expression in the peritoneum 
To better characterize infiltrated fibrocytes in the peritoneum, dual-immunostaining 
for CCR2 and Col I was performed.  Numerous CCR2-positive fibrocytes were 
detected in the peritoneum after CG injection (Figure 3a-c).  The number of 
CCR2-positive fibrocytes increased in accordance with the progression of fibrosis after 
CG injection, and was reduced in CG+FR mice (150.9±13.3/mm2) as compared with 
that in CG mice (406.7±39.8/mm2) (Figure 3d).  To elucidate the effect of 
p-p38MAPK signaling on peritoneal chemotactic molecules, the expression of CCL2 
was examined.  CCL2 protein was induced by CG injection in peritoneal mesothelial 
cells as well as interstitial cells (Figure 3e).  The mRNA transcripts for CCL2 were 
up-regulated in the peritoneum after CG injection, while the levels of CCL2 were 




Figure 2.  Fibrocyte infiltration in the peritoneum.   
Dual-immunostainings for CD45/Col I were performed (green: CD45, yellow: dual positive 
fibrocyte(arrows), red: Col I).  CD45/ Col I-dual positive fibrocytes infiltrated in the 
peritoneum after CG injection (a: Normal control at day 0, b: CG mice, c: CG+FR mice).  
Arrows indicate dual positive cells for CD45 and Col I.  d: The number of infiltrated 
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fibrocytes was reduced in mice treated with FR167653.  Values are mean SEM.  * P<0.01.  
Original magnifications, X200. 
 
 
Figure 3.  CCR2-expressing fibrocytes and CCL2 production in the peritoneum. 
Dual-immunostainings for CCR2/Col I were performed (green: CCR2, yellow: CCR2-positive 
fibrocyte(arrows), red: Col I).  CCR2-positive fibrocytes were detected in the peritoneum after 
CG injection (a: Normal control at day 0, b: CG mice, c: CG+FR mice).  White arrows 
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indicate dual positive cells for CCR2 and Col I.  d: The number of infiltrated CCR2-positive 
fibrocytes was reduced in mice treated with FR167653.  e: The production of CCL2 protein 
was induced by CG injection in peritoneal mesothelial cells as well as interstitial cells.  Yellow 
arrows indicate CCL2-positive cells.  f: mRNA transcripts for CCL2 in the peritoneum after 
CG injection were up-regulated, while the levels of CCL2 were reduced in mice treated with 
FR167653.  Values are mean ±SEM.  * P<0.01.  **P<0.05.  Original magnifications, 
X200. 
 
Phosphorylated p38MAPK-positive cells in the peritoneum 
Immunohistochemical studies were performed in order to clarify the localization of 
p-p38MAPK-positive cells in the peritoneum.  p-p38MAPK-positive cells were 
detected in peritoneal mesothelial cells as well as interstitial cells in thickened 
peritoneum after CG injection (Figure 4a).  The percentages of p-p38MAPK-positive 
mesothelial cells in CG mice were higher than that in CG+FR mice (Figure 4b).  In 
addition, the number of interstitial p-p38MAPK-positive cells in the peritoneum was 
reduced in CG+FR mice compared with that in CG mice (Figure 4c). 
 
 
Figure 4.  The presence of p-p38MAPK positive cells in the peritoneum. 
a: Arrows indicate p-p38MAPK positive mesothelial cells. Arrowheads indicate 
p-p38MAPK-positive spindle-shaped cells.  b: The percentage of p-p38MAPK-positive 
mesothelial cells in peritoneum was decreased in mice treated with FR167653.  c: The number 
of interstitial p38MAPK-positive cells in the peritoneum was significantly reduced in mice 
treated with FR167653.  Values are mean ±SEM.  * P<0.01.  Original magnifications, 
X200. 
 
CD45/phosphorylated p38MAPK-dual positive cells in the peritoneum 
To confirm the identity of peritoneal p-p38 MAPK-positive cells, dual 
immunostaining for CD45 and p-p38MAPK was performed.  A portion of the 
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CD45/p-p38MAPK-dual positive cells comprised spindle-shaped cells, suggesting the 
presence of p-p38MAPK-positive fibrocytes (Figure 5a-c).  The number of 
CD45/p-p38MAPK-dual positive spindle-shaped cells in the peritoneum was reduced in 
CG+FR mice compared with that in CG mice (Figure 5d). 
 
 
Figure 5.  The characterization of peritoneal p-p38MAPK-positive cells.   
Dual-immunostainings for CD45/p-p38MAPK were performed (brown: p-p38MAPK, red: 
CD45).  Arrows indicate CD45/p-p38MAPK-dual positive spindle-shaped cells (a: Normal 
control at day 0, b: CG mice, c: CG+FR mice).  d: The number of CD45/p-p38MAPK-dual 
positive spindle-shaped cells was reduced in mice treated with FR167653.  Values are mean 
±SEM.  * P<0.01.  **P<0.05.  Original magnifications, X200. 
 
The production of COLIAI mRNA in isolated fibrocyte was reduced by the 
treatment with FR167653 
The impact of p38MAPK signaling on COLIAI expression in isolated fibrocytes 
was examined in vitro.  Circulating fibrocytes were isolated from human peripheral 
blood (>97% pure population of cells coexpressing CD45 and Col I), cultured in 
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DMEM/0.5% heat-inactivated FCS for 24 hours, and then stimulated with TGF-  
(10ng/mL) for 24 hours.  Stimulation with TGF- 1 increased the expression of 
COLIAI while pretreatment with FR167653 abrogated TGF- 1-induced expression of 
COLIAI (Figure 6). 
 
 
Figure 6.  The effect of p38MAPK on the production of procollagen typeI 1 (COLIAI).   
The production of COLIAI mRNA in isolated fibrocytes was induced by the stimulation of 





In this study, we provide evidence for the infiltration of fibrocytes in the peritoneum 
in a murine peritoneal fibrosis model.  The number of fibrocytes in the peritoneum 
increased in accordance with the progression of peritoneal fibrosis.  The infiltrated 
fibrocytes expressed the chemokine receptor CCR2 and an increase in the 
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phosphorylation of p38MAPK was detected in peritoneal mesothelial cells and 
interstitial cells including fibrocytes.  The number of p-p38MAPK-positive cells as 
well as the level of peritoneal CCL2 expression was associated with the severity of 
fibrosis.  Pharmacologic inhibition of p38MAPK signaling reduced the extent of 
fibrosis, the number of fibrocytes and p-p38MAPK-positive cells, and the peritoneal 
expression of peritoneal CCL2.  Furthermore, inhibition of p38MAPK signaling 
attenuated the expression of COLIAI induced by the stimulation with TGF- 1 in 
cultured fibrocytes.  These results suggest that the p38MAPK pathway contribute to 
the pathogenesis of peritoneal fibrosis through the infiltration and activation of 
fibrocytes. 
The activation of p38MAPK signaling is involved in the pathogenesis of renal and 
pulmonary fibrosis via the up-regulation of pro-inflammatory mediators  [10, 
11,17,18,20,21,25].  The phosphorylation of p38MAPK has been demonstrated in 
resident cells including renal tubular epithelial cells (RTECs) both in an experimental 
renal fibrosis model and human renal diseases [20,21].  The present study also 
revealed the phosphorylation of p38MAPK in peritoneal mesothelial cells.  RTECs as 
well as peritoneal mesothelial cells have been reported to be capable of producing 
chemokines via p38MAPK signaling cascades [26,27].  The number of 
p-p38MAPK-positive cells as well as the level of CCL2 expression in mesothelial cells 
also increased concomitantly with disease progression, while the treatment with 
FR167653 reduced those changes.  From these findings, p38MAPK may contribute to 
the production of CCL2 in peritoneal mesothelial cells, thereby promoting the 
pathogenesis of peritoneal fibrosis. 
The infiltration of fibrocytes into diseased organs has been reported to be regulated 
by chemokine-chemokine receptor systems, including CCL2 and its receptor CCR2 
[4-6,9,28].  In addition, the inhibition of CCR2/CCL2 system has been shown to 
ameliorate the infiltration of fibrocytes and the severity of fibrosis in a murine 
pulmonary fibrosis model [9].  In the present study, the blockade of p38MAPK 
signaling reduced the number of CCR2-expressing fibrocytes in accordance with the 
levels of CCL2 expression as well as the intensity of peritoneal fibrosis, suggesting that 
the CCR2/CCL2 system is dependent on p38MAPK.  The potential roles of other 
chemokine systems including CCR7/CCL21 and CXCR4/CXCL12 in the pathogenesis 
of peritoneal fibrosis remain to be determined. 
Finally, we observed that the expression of COLIAI in cultured fibrocytes was 
observed to be enhanced by the stimulation with TGF-1, and pre-treatment with 
FR167653 abrogated the expression of COLIAI.  p38MAPK signaling thus may 
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contribute additionally to the pathogenesis of peritoneal fibrosis by directly regulating 
the production of collagen in fibrocytes.  Such a pathway has previously been 
suggested in studies of pro-collagen type I and fibronectin expression by scleroderma 
fibroblasts [29].  Furthermore, CCR2-expressing fibrocytes have been shown to 
express type I pro-collagen in response to stimulation with CCL2 in a murine 
pulmonary fibrosis model [9].   
 
 
Figure 7.  Proposed schema for p38MAPK signaling in the pathogenesis of peritoneal fibrosis 
through (1) the regulation of fibrocytes infiltration via CCL2 production and (2) production of 




Our results suggest that p38MAPK signaling is involved in the pathogenesis of 
peritoneal fibrosis through the regulation of fibrocyte infiltration and collagen 
production (Figure7). Inhibition of the recruitment and activation of fibrocytes with 
p38MAPK signal transduction could provide a novel therapeutic approach for 
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